Retatrutide vs Saxenda: Third-Gen vs First-Gen GLP-1

Retatrutide and Saxenda (liraglutide) both belong to the GLP-1 receptor agonist family, but they represent the first and third generations of this drug class. Saxenda, approved in 2014, was the first GLP-1 specifically approved for weight management, producing about 8% average weight loss with daily injections. Retatrutide, a triple agonist hitting GLP-1, GIP, and glucagon receptors, achieved 24.2% weight loss with weekly injections in Phase 2 trials (Jastreboff et al., NEJM 2023). The evolution from Saxenda to retatrutide illustrates how rapidly obesity pharmacology is advancing.

Three Generations of GLP-1 Therapy

Understanding the Saxenda-to-retatrutide progression requires seeing the three generations clearly. First generation: liraglutide (Saxenda) — a once-daily GLP-1 agonist that proved the concept. Second generation: semaglutide (Wegovy) — a once-weekly GLP-1 agonist with improved potency and convenience. Third generation: retatrutide — a once-weekly triple agonist that adds GIP and glucagon to GLP-1.

Each generation roughly doubled weight loss: Saxenda at ~8%, Wegovy at ~15%, retatrutide at ~24%. Each generation also improved convenience, moving from daily to weekly injections. This trajectory suggests that we are still in the early stages of what obesity pharmacotherapy can achieve.

Head-to-Head Comparison

Why Saxenda Is Being Replaced

Saxenda was groundbreaking when it launched. It proved that GLP-1 receptor agonists could be effective weight loss medications, not just diabetes treatments. But its limitations are now clear: daily injections are burdensome, 8% average weight loss is modest by current standards, and single-receptor GLP-1 activation misses important metabolic pathways.

The arrival of semaglutide (Wegovy) in 2021 already made Saxenda largely obsolete for most patients — weekly injections and double the weight loss made the choice straightforward. Retatrutide will extend this gap further, producing three times Saxenda's weight loss with the same weekly injection convenience as semaglutide.

Side Effects: Similar but Different

Both drugs share GI side effects from GLP-1 activation. Saxenda's nausea rate is approximately 39% — actually higher than retatrutide's 26%. This counterintuitive finding may relate to daily dosing creating more GI stimulation than weekly dosing, or to the receptor balance in retatrutide moderating pure GLP-1 effects.

Retatrutide adds glucagon-specific effects (mild heart rate increase, potential liver enzyme elevation, dysesthesia) that Saxenda lacks. However, the overall discontinuation rates due to side effects are comparable or lower with retatrutide, suggesting these additional effects are manageable.

If You Are Currently on Saxenda

Patients currently taking Saxenda should discuss transitioning to a more effective medication with their physician. Semaglutide and tirzepatide are available now and produce significantly better results. Transitioning from a GLP-1 agonist to another is straightforward since the mechanisms overlap.

Trimi offers compounded semaglutide at $99/month and compounded tirzepatide at $125/month — both significantly cheaper than Saxenda's $1,349/month brand price, and both significantly more effective. Get started with Trimi today.

Frequently Asked Questions

Is retatrutide better than Saxenda?

By every clinical measure, yes. Retatrutide produces approximately three times more weight loss (24.2% vs 8%), requires less frequent injections (weekly vs daily), and provides broader metabolic benefits through triple receptor activation.

Should I switch from Saxenda to semaglutide?

For most patients, yes. Semaglutide (Wegovy/Ozempic) produces about double the weight loss of Saxenda with weekly instead of daily injections. Compounded semaglutide through Trimi is also significantly more affordable.

Is Saxenda still worth taking?

Saxenda may still be appropriate for patients who have insurance coverage specifically for Saxenda, who have contraindications to semaglutide or tirzepatide, or who had good results on Saxenda and prefer not to switch. For new patients, more effective options are recommended.

Will Saxenda be discontinued?

Novo Nordisk has not announced plans to discontinue Saxenda. However, prescribing volume is declining as semaglutide becomes the standard of care. Saxenda's role will likely continue to shrink as newer medications become available.